3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Hypersensitivity
2
Fallopian Tube Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
290
Capecitabine
206
Fluorouracil
181
Cisplatin
168
Docetaxel
138
S 1 (combination)
132
Paclitaxel
121
Leucovorin
116
Irinotecan
106
pembrolizumab
103
Trastuzumab
71
apatinib
56
Nivolumab
56
sintilimab
45
Drug Therapy
43
Surgical Procedures, Operative
37
Radiotherapy
37
Bevacizumab
37
Ramucirumab
34
titanium silicide
31
Hyperthermic Intraperitoneal Chemotherapy
30
Epirubicin
30
Carboplatin
30
tislelizumab
28
Cyclophosphamide
27
XELOX
24
Tegafur
23
Folfox protocol
22
Albumin-Bound Paclitaxel
22
camrelizumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Stomach Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled